Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics


Ionis Pharmaceuticals, Inc. (IONS): $37.93

-0.28 (-0.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IONS POWR Grades


  • Value is the dimension where IONS ranks best; there it ranks ahead of 67.21% of US stocks.
  • The strongest trend for IONS is in Growth, which has been heading up over the past 31 weeks.
  • IONS ranks lowest in Sentiment; there it ranks in the 3rd percentile.

IONS Stock Summary

  • IONS's went public 30.08 years ago, making it older than 83.48% of listed US stocks we're tracking.
  • In terms of twelve month growth in earnings before interest and taxes, Ionis Pharmaceuticals Inc is reporting a growth rate of -162.33%; that's higher than merely 12.76% of US stocks.
  • Revenue growth over the past 12 months for Ionis Pharmaceuticals Inc comes in at -26.21%, a number that bests just 15.01% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ionis Pharmaceuticals Inc are RLAY, CLDR, NERV, DRIO, and VRAY.
  • Visit IONS's SEC page to see the company's official filings. To visit the company's web site, go to www.ionispharma.com.

IONS Price Target

For more insight on analysts targets of IONS, see our IONS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $57.83 Average Broker Recommendation 1.82 (Hold)

IONS Stock Price Chart Interactive Chart >

Price chart for IONS

IONS Price/Volume Stats

Current price $37.93 52-week high $64.37
Prev. close $38.21 52-week low $34.43
Day low $37.44 Volume 1,393,600
Day high $38.48 Avg. volume 1,487,838
50-day MA $39.45 Dividend yield N/A
200-day MA $49.30 Market Cap 5.35B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio


Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.


IONS Latest News Stream


Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream


Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about Ionis Pharmaceuticals Inc that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Ionis'' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

CARLSBAD, Calif., June 10, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society

PR Newswire | June 10, 2021

Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021. Ionis' participation highlights the advancements it's made in developing novel antisense therapies for ATTR and underscores Ionis' commitment to this patient community.

Yahoo | June 10, 2021

New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy

New data analysis suggests an investigational higher dose of SPINRAZA may lead to clinically meaningful improvements in motor functionA NURTURE study analysis shows 92 percent of children who initiated SPINRAZA treatment as pre-symptomatic infants maintained the ability to swallow after approximately 4 yearsAmong children and teens with later-onset SMA in the SHINE study, long-term treatment with SPINRAZA improved walking distance and reduced fatigue CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWI

Yahoo | June 10, 2021

Why Is Ionis Pharmaceuticals (IONS) Down 7% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 4, 2021

Ionis announces changes to its board of directors at annual meeting of stockholders

CARLSBAD, Calif., June 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board. As previously announced,

PR Newswire | June 2, 2021

Read More 'IONS' Stories Here

IONS Price Returns

1-mo -0.81%
3-mo -30.56%
6-mo -26.33%
1-year -35.02%
3-year -19.89%
5-year 69.71%
YTD -32.91%
2020 -6.41%
2019 11.75%
2018 7.48%
2017 5.16%
2016 -22.77%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7812 seconds.